about
Patient-derived tumour xenografts for breast cancer drug discoveryPhase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors.Circulating Tumor DNA in a Breast Cancer Patient's Plasma Represents Driver Alterations in the Tumor Tissue.Cyclin D mediates tolerance of genome-doubling in cancers with functional p53.ETS-targeted therapy: can it substitute for MEK inhibitors?Retinoic acid receptor alpha drives cell cycle progression and is associated with increased sensitivity to retinoids in T-cell lymphoma.CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers.High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers.Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?Progress with palbociclib in breast cancer: latest evidence and clinical considerations.Superior anti-tumor efficacy of diisopropylamine dichloroacetate compared with dichloroacetate in a subcutaneous transplantation breast tumor model.LncRNA SNHG12 promotes cell growth and inhibits cell apoptosis in colorectal cancer cells.Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma.Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer.miR‑150 inhibits proliferation and tumorigenicity via retarding G1/S phase transition in nasopharyngeal carcinoma.Loss of MutL Disrupts Chk2-dependent Cell Cycle Control Through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.Diverse gene expression patterns in response to anticancer drugs between human and mouse cell lines revealed by a comparative transcriptomic analysis.Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer.A genetic interaction analysis identifies cancer drivers that modify EGFR dependency.Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.Advances in chemical pharmacotherapy to manage advanced breast cancer.Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth.Cellular senescence in renal ageing and disease.The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies.Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure.A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.A Mathematical Model of Cell Cycle Dysregulation Due to Human Papillomavirus Infection.Novel Pieces for the Emerging Picture of Sulfoximines in Drug Discovery: Synthesis and Evaluation of Sulfoximine Analogues of Marketed Drugs and Advanced Clinical Candidates.The awakening of the CDK10/Cyclin M protein kinase.Synthesis, molecular modeling and anticancer activity of new coumarin containing compounds.Unintended target effect of anti-BCL-2 DNAi.Structural basis of divergent cyclin-dependent kinase activation by Spy1/RINGO proteins.Epigenetic mediated zinc finger protein 671 downregulation promotes cell proliferation and tumorigenicity in nasopharyngeal carcinoma by inhibiting cell cycle arrest.Ensemble-based modeling and rigidity decomposition of allosteric interaction networks and communication pathways in cyclin-dependent kinases: Differentiating kinase clients of the Hsp90-Cdc37 chaperone.Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.PFOS induces proliferation, cell-cycle progression, and malignant phenotype in human breast epithelial cells.Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer.
P2860
Q28080046-3B8DF1E7-B5E8-473D-8804-16212AD86E27Q33441161-95F5072C-9DAC-4CC5-A92F-F08402648404Q33559104-F9255804-AFBE-4A37-A298-5D6ED4EE6AAFQ33564829-B1CC4373-D7E3-4A33-8A06-8E5DDDF9A971Q33638827-9BEAE01D-67CE-40CD-AA12-CA78F9819979Q33688613-5B974539-1A5D-4082-AD7D-4019A8E0218FQ33851230-AD7C7AC5-7B65-46EB-A79F-F34BD33FF671Q33867326-C71B24C8-1E76-4191-A3D2-3E29B42DF79FQ37631514-44CF751B-4BC5-44B9-9E92-344DAA8976F9Q37632170-1A7C3FAB-041E-4D22-AA25-CC2E7DA8990BQ37662302-83A59602-3A66-473E-A265-57D8E8BCA236Q37677207-E3FF565C-2F37-4DC6-9AB9-15C50714E5CBQ37696112-7C3D9D60-3C79-4D46-B778-7592AD859120Q37716464-7E900A52-2708-483C-A32B-19A53CE5DCDCQ37718685-80189DD8-2C94-473F-9B98-41240EAEA498Q38628334-3942138A-3B68-4668-9594-D87267364087Q38632866-C407A289-70CC-4123-943A-CE0378496812Q38649485-551D55F6-6635-41CB-B749-02D677B10A34Q38700527-53C9CA7D-6C80-407E-899A-022F779CCA73Q38717620-704E594A-5AEE-461D-BBD4-2257D8F4258DQ38723234-6DE9942B-AA74-44F1-87A2-291961F4E461Q38786066-33B88985-801D-4AFE-932D-A2AF2B6226A3Q38832541-4D57252B-EC00-4F8B-9E2E-AFF9D5BA4190Q39048659-2E385E09-D118-4396-A694-408BF72CDAE7Q39060497-A2A553D0-1407-41FE-B93A-7421A76D1498Q39183079-E97A247E-4270-4E03-BE72-B8D3B8DEA393Q39204274-5A2598A8-2051-4C2A-BFAE-942DCDF251B6Q39289608-C7245640-7D35-4FFB-999E-57932FA6BBB8Q39402106-3942EF06-5B3C-49A0-83BF-3EFF91F12A5DQ40174845-AEE7AB63-7161-4E20-B750-296CB812821CQ41039819-7B102001-17DA-4C48-B84B-7BCCE3F97FBCQ41472998-7CEA2C86-D7E8-4D6F-8C81-566359ACE629Q41690458-74CD69AC-25A7-4FBB-A826-7E60BB59D15EQ42286844-2D7C1C2C-6374-45DA-A355-B0C9E7418DB4Q42428328-4A70E753-0075-4A93-BD88-2943CD9D6FE5Q42668878-92EF38F9-17FC-4759-B93E-53E52401EA99Q45335193-5CB1A143-D93A-4762-B4DB-DE2007B97114Q45348344-ADC88778-A78F-4FB2-A789-E09DD49B9A00Q46276468-ACC68142-818A-4F98-9C0C-EF53F738A031Q46420204-017BEB08-AAB8-4A28-95CE-8BEC3DD2FE92
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Treating cancer with selective CDK4/6 inhibitors.
@en
type
label
Treating cancer with selective CDK4/6 inhibitors.
@en
prefLabel
Treating cancer with selective CDK4/6 inhibitors.
@en
P1476
Treating cancer with selective CDK4/6 inhibitors.
@en
P2093
Nicholas C Turner
Richard S Finn
P304
P356
10.1038/NRCLINONC.2016.26
P407
P50
P577
2016-03-31T00:00:00Z